跳至主要内容
临床试验/NCT06666634
NCT06666634已完成不适用

Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node Biopsy

The Netherlands Cancer Institute1 个研究点 分布在 1 个国家目标入组 29 人开始时间: 2023年4月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
29
试验地点
1
主要终点
Concordance between tracers

研究概览

简要总结

99mTc-nanocolloid, the world wide used hybrid tracer for dynamic sentinel node biopsy, has recently been replaced with 99mTc-nanoscan. The hybrid form (ICG-99mTc-nanoscan) has not yet been validated, to show the similarity between the lymphatic drainage pattern between ICG-99mTc-nanoscan and 99mTc-nanoscan.

详细描述

The investigators want to set up this study in analogy with the comparison study which was conducted before the introduction of ICG-99mTc-Nanocolloid (99mTc-Nanocoll vs. ICG-99mTc-Nanocoll (NL26699.031.09 -N09DRF). In particular, the investigators want to validate that the hybrid ICG-99m Tc-Nanoscan shows the same preoperative gland involvement on preoperative lymphoscintigraphy and that the intraoperative signal intensities remain the same. All this to maintain the level of current care.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patient who will undergo a sentinel node procedure in routine care.
  • •Patients > 18 years;
  • •Patients presenting with:
  • •a primary cutaneous melanoma of head/neck or upper part of the trunk or extremities;
  • •OR patients presenting with a primary oral cavity malignancy T1-2N0
  • •OR patients with primary penile cancer
  • •Patients with clinical N0 stage;
  • •Patients scheduled for a sentinel node biopsy prior to (re-)excision of the primary lesion;
  • •Patients in which ICG-99mTc-nanoscan would be used in routine care or a research setting

排除标准

  • •Patients with known allergy to patent blue dye or nanocolloid;
  • •Patients who are pregnant or breast-feeding mothers;
  • •History of hypersensitivity reactions to products containing human serum albumin;
  • •History of iodine allergy
  • •Hyperthyroid or thyroidal adenoma
  • •Kidney insufficiency
  • •Incapacity or unwillingness of participant to give written informed consent;

研究组 & 干预措施

Dynamic sentinel node biopsy with 99mTc-nanoscan and ICG-99mTc-nanoscan

Other

The patient first receives a one-time injection with 99mTc-nanoscan, then a one-time injection with ICG-99mTc-nanoscan, both dosage are according to routine care.

干预措施: Sentinel node biopsy with either ICG-99mTc-nanoscan or 99mTc-nanoscan (Drug)

结局指标

主要结局

Concordance between tracers

时间窗: Measured at pre-operative imaging

To demonstrate concordance between the SN visualization of 99mTc-nanoscan and ICG-99mTc-nanoscan on preoperative lymphoscintigraphy and SPECT/CT imaging, expecting an average of 3 sentinel nodes per patient. Discordance is defined as more than 1 sentinel node not detected coherently by the tracers.

次要结局

  • Concordance between intraoperative fluorescence and radioactive findings(Measured at pre-operative imaging)
  • Higher echelon nodes(Measured at pre-operative imaging)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验